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ABSTRACT: Four compounds that contained the N-benzyl 2-
amino-3-methoxypropionamide unit were evaluated for their ability
to modulate Na+ currents in catecholamine A differentiated CAD
neuronal cells. The compounds differed by the absence or presence
of either a terminal N-acetyl group or a (3-fluoro)benzyloxy moiety
positioned at the 4′-benzylamide site. Analysis of whole-cell patch-
clamp electrophysiology data showed that the incorporation of the
(3-fluoro)benzyloxy unit, to give the (3-fluoro)benzyloxyphenyl
pharmacophore, dramatically enhanced the magnitude of Na+
channel slow inactivation. In addition, N-acetylation markedly
increased the stereoselectivity for Na+ channel slow inactivation.
Furthermore, we observed that Na+ channel frequency (use)-dependent block was maintained upon inclusion of this
pharmacophore. Confirmation of the importance of the (3-fluoro)benzyloxyphenyl pharmacophore was shown by examining
compounds where the N-benzyl 2-amino-3-methoxypropionamide unit was replaced by a N-benzyl 2-amino-3-
methylpropionamide moiety, as well as examining a series of compounds that did not contain an amino acid group but
retained the pharmacophore unit. Collectively, the data indicated that the (3-fluoro)benzyloxyphenyl unit is a novel
pharmacophore for the modulation of Na+ currents.
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Epilepsy is a serious neurological disorder affecting up to 1%of the world’s population.1 It is a common misconception
that epilepsy is a single disease; rather, epilepsy is a
heterogeneous mixture of disorders characterized by reoccur-
ring, unprovoked seizures that result from neuronal hyper-
excitability and hypersynchronous neuronal firing.1,2 Pharma-
cological management is the primary treatment option, but 30%
of patients are pharmacoresistant and do not respond to at least
two of the first-line antiepileptic drugs (AEDs),3 and those who
do respond often experience adverse side effects (e.g.,
drowsiness, dizziness, nausea).4 Therefore, new AEDs with
novel mechanisms of action are needed to improve the outlook
of the pharmacological management of epilepsy.
We have reported on the anticonvulsant activities in the
maximal electroshock seizure (MES) model5 of four classes of
compounds that contained an N-benzyl 2-amino-3-methoxy-
propionamide (A) structural unit, where the R and R′
substituents and the C(2) stereochemistry were varied.6−12
Included in this set was the parent compound 1 (R, R′ =
H),7,8,11 the N-acetylated derivative 2 (R = CH3C(O), R′ =
H),6 the 4′-benzyl modified compound 3 (R = H, R′ =
OCH2Ph(m-F)),
12 and the disubstituted analogue 4 (R =
CH3C(O), R′ = OCH2Ph(m-F)).10 We observed that 2−4
exhibited potent anticonvulsant activities,6,10,12 and that for
compounds 1−4, increased anticonvulsant activity was
associated with the D-amino acid configuration ((R)-stereo-
isomer).6,8,10−12 The anticonvulsant activities of (R)-2, (R)-3,
and (R)-4 rivaled the anticonvulsant activities of clinically used
AEDs.13 One of these compounds, (R)-N-benzyl 2-acetamido-
3-methoxypropionamide6 (lacosamide, (R)-2), is a first-in-class
AED marketed in 34 countries, including the United States.14
Studies have shown that (R)-2 preferentially transitioned
voltage-gated Na+ channels (VGSCs) to the slow inactivation
state without affecting fast inactivation.15−17 Na+ channel slow
inactivation promotion is a powerful mechanism to control the
hyperexcitable neuron in the epileptic patient, where neurons
are either rapidly firing or in a sustained, depolarized state.
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Neuropathic pain, like epilepsy, results from neuronal hyper-
excitability.18 Compound (R)-2 has been evaluated in several
neuropathic pain animal models with success,19 a finding
consistent with pharmacological and clinical studies that
document the similarities in the pathophysiological phenomena
observed in epilepsy and neuropathic pain models.20,21
In this investigation, we compare the Na+ channel properties
of 1 and 3 with those reported for 215−17 and 4.10,22 We show
that (R)-1, like (R)-2, promotes Na+ channel slow inactivation,
and that N-acetylation of the terminal amine in (R)-1 markedly
increases the stereoselectivity of this process. We further
document that 4′-aryl extension of (R)-1 and (R)-2 to give (R)-
3 and (R)-4, respectively, dramatically enhance Na+ channel
slow inactivation. Analysis of the data identifies the substituted
benzyloxyphenyl (B) unit as a pharmacophore that can
transition Na+ channels to the slow inactivation conformation.
We confirm these findings by testing the Na+ channel
properties of additional compounds.
■ RESULTS AND DISCUSSION
Choice of Compounds and Synthesis. Our initial study
on the effect of chemical structure on Na+ channel modulation
was restricted to compounds 1−4 that contained the N-benzyl
2-amino-3-methoxypropionamide (A) moiety. Our previous
studies guided our compound selection.6,10−12 Compounds
(R)-2−(R)-4 exhibited excellent anticonvulsant activity in the
MES test (MES ED50 (mg/kg, mice (ip): (R)-2, 4.5; (R)-3, 15;
(R)-4, 13)) that exceeded the anticonvulsant activity of
phenobarbital (MES ED50 = 22 mg/kg) (Table 1). Compounds
1 and 3 did not possess an N-acetyl moiety, while 2 and 4 did.
Compounds 3 and 4 are 4′-aryl extended analogs of 1 and 2,
respectively. For compounds 1, 2, and 4, we examined both the
(R)- and (S)-stereoisomers because anticonvulsant activity was
associated with the (R)-configuration.6,10,11 The Na+ channel
properties observed for 1−4 prompted us to investigate amino
acid derivatives that did not contain the 2-amino-3-methox-
ypropionic acid unit, but still possessed either the N-benzyl
amide or the N-4′-(3-fluoro)benzyloxybenzyl amide group seen
in either 1 and 2, or 3 and 4, respectively. Thus, we examined
(R)-5,11 (S)-5,11 and (R)-6,12 where we replaced the 2-amino-
3-methoxypropionic acid unit with a 2-amino-3-methylpro-
pionic acid group. We chose (R)-5 and (R)-6 because of their
excellent anticonvulsant activities in the MES test.11,12
Compound (R)-5 was one the most potent C(2)-hydrocarbon
derivatives tested.11 The MES ED50 values in mice (ip) for (R)-
5 and (R)-6 were 15 and 12 mg/kg, respectively (Table 1).
Notably, (R)-6 contained both a 2-amino-3-methylpropionic
acid group and a (3-fluoro)benzyloxyphenyl unit.
Next, we tested compounds 7−9. All three compounds
possessed a 4′-(3-fluoro)benzyloxyphenyl unit, but did not
contain an amino acid group. The synthesis of 1−6, 8, and 9
were previously reported, and compound 7 is commercially
available.
Modulation of Na+ Channel Slow Inactivation by
Compounds 1−4. Using the whole-cell patch-clamp config-
uration, we examined the effects of 1−4 on VGSCs in the
catecholamine A differentiated (CAD) neuronal cell line. We
have previously shown that CAD cells were surrogates of
neuronal cell lines and express endogenous tetrodotoxin-
sensitive Na+ currents with rapid activation and inactivation
upon membrane depolarization, and are likely composed of
NaV1.7, NaV1.1, and NaV1.3 channels.
23 NaV1.7 mRNA is
expressed at 15- and 30-fold higher levels compared with
mRNAs of NaV1.1 and NaV1.3, respectively.
23 Consistent with
this level of expression, we confirmed that the majority of the
NaV current was carried via NaV1.7, as >55% of the current was
blocked by NaV1.7-selective protox II (10 nM, see Figure 8A,
B). We previously found that the Na+ channel properties of
(R)-2 in CAD cells23 were similar to those reported in cultured
rat cortical neurons and mouse N1E-115 neuroblastoma cells.15
Accordingly, we initially used readily accessible CAD cells to
evaluate the effect of structure on neuronal function,
recognizing in advance that CAD cells do not express the
same complement of Na+ channels expressed in CNS neurons.
In additional pilot studies, we verified that (R)-1−(R)-4, as well
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Table 1. Anticonvulsant and Electrophysiology Data for Test Compounds
aThe compounds were administered intraperitoneally to adult male albino CF-1 mice or NMRI mice. ED50 and TD50 values are in mg/kg. A dose−
response curve was generated for all compounds that displayed sufficient activity and the dose−effect data for these compounds was obtained at the
“time of peak effect” (indicated in hours in the brackets). Numbers in parentheses are 95% confidence intervals. bThe compounds were administered
orally to adult male albino Sprague−Dawley rats. ED50 and TD50 values are in mg/kg. cMES = maximal electroshock seizure test. dTox =
neurological toxicity. TD50 value determined from the rotorod test.
eTox = behavioral toxicity. fIC50, Concentration at which half of the Na
+ channels
have transitioned to a slow inactivated state. gReference 11. hND = not determined. iReference 6. jReference 12. kReference 10. lReference 13. mNS
= not selective for slow inactivation.
ACS Chemical Neuroscience Research Article
dx.doi.org/10.1021/cn300129d | ACS Chem. Neurosci. 2012, 3, 1037−10491039
as their enantiomers, were capable of inhibiting Na+ currents in
CAD cells without affecting reversal potential (data not
shown), half-maximal activation (see Figure 3), or slope
parameters (data not shown).
To measure the effect of compounds 1−4 on Na+ channel
slow inactivation, a cardinal feature of (R)-223 and (R)-4,22 we
held CAD cells at −80 mV and conditioned them to potentials
ranging from −120 mV to +20 mV (in 10 mV increments) for
5 s.22,23 Then, fast-inactivated channels were allowed to recover
for 150 ms at a hyperpolarized pulse to −120 mV, and the
fraction of channels available was tested by a single depolarizing
pulse to 0 mV for 15 ms. This brief hyperpolarization allowed
the channels to recover from fast inactivation while limiting
recovery from slow inactivation. Using this protocol (Figure
1A), we generated a series of compound response curves
showing the normalized peak (INa) versus prepulse potential
(mV) at a given compound concentration. The maximal IC50
values (in μM) at +20 mV for each compound listed in Table 1
were determined from the response curves generated from a
series of compound concentrations. The +20 mV potential was
chosen because maximal slow inactivation is achieved at this
potential, and derivation of maximal IC50 values is likely to
unmask even subtle effects of chemical modification to the test
compounds on slow inactivation. To illustrate the effects of
compounds on slow inactivation, we have also presented the
data at −50 mV. The potential of −50 mV was chosen for three
reasons: (1) a large fraction of the channels undergo steady-
state inactivation, which involves contributions from slow and
fast inactivation pathways,24,25 where −50 mV is within the
steep voltage-dependence range for each, (2) it is near the
resting membrane potential and approaches the action potential
firing threshold for central nervous system neurons,26 where
slow inactivation appears to be physiologically relevant during
sustained subthreshold depolarizations,27 and (3) changes in
the Na+ channel availability near −50 mV can impact the
overlap of Na+ current activation and inactivation under steady-
state conditions.25,28 Representative traces illustrating the
extent of slow inactivation observed at −50 mV compared to
the prepulse at −10 mV in the absence or presence of (R)-1,
(S)-1, and (R)-3 are shown in Figure 1B, with complete slow
inactivation curves (normalized peak versus prepulse potential)
shown in Figure 1C. A lesser concentration of (R)-3 (100 μM
versus 500 μM for (R)-1 and (R)-2), in which the (3-
fluoro)benzyloxy substituent has been appended to the 4′-
benzyl site in (R)-1 to provide the (3-fluoro)benzyloxyphenyl
pharmacophore, is shown to highlight the superior slow
inactivation-promoting capability of (R)-3 compared with
(R)-1 and (R)-2 (Figure 1C, D). Importantly, (R)-4, which
has both a 4′-(3-fluoro)benzyloxy substituent and a N-acetyl
moiety, demonstrated the highest extent of slow inactivation, as
even 30 μM of (R)-4 was better at transitioning Na+ channels
into the slow inactivated state compared with 100 μM or more
of (R)-1, (S)-1, and (R)-3 (Figure 1D).
N-Acetylation of N-benzyl 2-amino-3-methoxypropionamide
(1) to provide N-benzyl 2-acetamido-3-methoxypropionamide
(2) markedly increased the stereoselectivity for Na+ channel
slow inactivation (maximal slow inactivation IC50 at +20 mV):
(S)-1/(R)-1 = 0.81; (S)-2/(R)-2 = > 21) (Figure 2). We found
a more dramatic change in the stereoselectivity in Na+ channel
slow inactivation modulation for 4, which contained both the
4′-(3-fluoro)benzyloxyphenyl substituent and the N-acetyl
moiety. The maximal slow inactivation IC50 ratio at +20 mV
for (S)-4/(R)-4 was 1100, indicating that the combination of
the N-acetyl and the (3-fluoro)benzyloxyphenyl moieties
increased both the potency and the stereoselectivity for Na+
channel function. Together these results demonstrated that
Figure 1. Effect of N-acetylation and 4′-aryl extension in N-benzyl 2-
amino-3-methoxypropionamide derivatives on slow inactivated Na+
currents in CAD cells. (A) Voltage protocol for slow inactivation:
currents were evoked by 5 s prepulses between −120 and +20 mV, and
then fast inactivated channels were allowed to recover for 150 ms at a
hyperpolarized pulse to −120 mV. The fraction of channels available at
0 mV was analyzed. (B) Representative current traces from CAD cells
in the absence (control, 0.1% DMSO; solid trace) or presence of 500
μM of (R)-1 and (S)-1, or 100 μM of (R)-3 (dashed traces). As a
comparator of the extent of slow inactivation, the control trace at
−120 mV (prepulse) is also shown (solid trace). (C) Summary of
steady-state, slow inactivation curves for CAD cells treated with
DMSO (control), 500 μM (R)-1 and (S)-1 or 100 μM (R)-3. Drug-
induced slow inactivation was almost equivalent in CAD cells treated
with (R)-1 and (S)-1, but was more prominent with (R)-3. Some error
bars are smaller than the symbols. In this and subsequent figures, data
are presented as means ± SEM. (D) Summary of the fraction of
current available at −50 mV for CAD cells in the absence or presence
of (R)- or (S)-enantiomers of the indicated compounds. Asterisks
indicate statistically significant differences in fraction of current
available between predrug and (R)- and (S)-compounds (p < 0.05,
one-way ANOVA with Dunnett’s posthoc test). Hash mark indicates a
statistically significant difference in fraction of current available
between (R)- and (S)-enantiomers. Numbers in parentheses are the
number of cells patched per condition. The half-maximal values for
slow inactivation for these compounds are shown in Table 1.
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(R)-4 is an effective ligand for the receptor(s) responsible for
mediating Na+ channel slow inactivation.
Modulation of Steady-State Activation, Fast Inactiva-
tion, and Frequency Dependent Block of Na+ Channels
by (R)-1−(R)-4. While promotion of slow inactivation is a
hallmark of (R)-2, we investigated if changing (R)-2 by either
deleting the N-acetyl moiety or adding the 4′-(3-fluoro)-
benzyloxy substituent affected other biophysical properties,
namely, steady-state activation, fast inactivation, and frequency-
dependent block. Changes in activation for the CAD cells
treated with the test compounds were measured by whole-cell
ionic conductances (in response to a voltage protocol shown in
Figure 3A, inset left) by comparing their midpoints (V1/2) and
slope factors (k) in response to changes in command voltage.
Representative Boltzmann fits for DMSO (control) and 30−
500 μM 1−4 are shown in Figure 3. An analysis of V1/2 and k
values derived from the Boltzmann fits showed that there were
no changes in the steady-state activation properties of Na+
currents between CAD cells treated with DMSO control or the
highest concentrations of 1−4 (data not shown). These data
indicate that the compounds do not affect the channel’s
transition from a closed to an open conformation.
In addition to affecting slow inactivation, stabilization of the
fast-inactivated conformation that is rapidly generated upon
channel firing is one possible way to control neuronal
hyperexcitability. Most anticonvulsants whose activity is
attributed, in part, to Na+ channel inactivation stabilize the
fast-inactivated conformation.29 Accordingly, we tested whether
1−4 affected Na+ channel fast inactivation using a protocol
designed to induce a fast-inactivated state (voltage protocol
shown in Figure 3B, inset right). Steady-state, fast inactivation
curves of Na+ currents from DMSO- and all 1−4-treated CAD
cells were well fitted with a single Boltzmann function (R2 >
0.9942 for all conditions). The V1/2 value for inactivation for
0.1% DMSO-treated cells was −68.2 ± 1.9 mV (n = 8), which
was significantly different from that of (R)-4 (30 μM)-treated
cells (−86.3 ± 3.2 mV; n = 8; p < 0.05; Student’s t test; Figure
3B). Compared with the ∼18.1 mV shift in V1/2 of fast
inactivation in the hyperpolarizing direction observed in the
presence of (R)-4, the shifts caused by the other compounds
were 15.8 mV, (S)-4 (500 μM; n = 6); 0.8 mV, (R)-1 (500 μM;
n = 7); 0.9 mV, (S)-1 (500 μM; n = 7); and 0.1 mV, (R)-3 (30
μM; n = 7; Figure 3) (p < 0.05 vs DMSO control; Student’s t
test). By comparison, we observed a 0.3 mV shift with (R)-2
(30 μM; n = 6) and (S)-2 (500 μM; n = 6), similar to the 0.7
mV shift 30 we had previously reported with (R)-2 (30
μM).22,23
Blockade of Na+ currents in an activity- or frequency (use)-
dependent manner is a useful property for AEDs because it
favors decreased Na+ channel activity during high-frequency
(i.e., seizures) but not low-frequency firing.22,29 Thus, we tested
if (R)-1−(R)-4 could elicit frequency-dependent block (Figure
4). In pilot experiments, we determined that concentrations up
to 100 μM did not affect fast inactivation; therefore, a
concentration of 30 μM was used to compare the effects of
(R)-1−(R)-4 on frequency-dependence. A train of 30 test
pulses (20 ms to −10 mV) was delivered from a holding
potential of −80 mV at 10 Hz.22 The available current in the
control and in the presence of the test compounds was
calculated by dividing the peak current at any given pulse
(pulseN) by the peak current in response to the initial pulse
(pulse1). We observed appreciable frequency-dependent block
for all compounds except (R)-2, with (R)-1, (R)-3, and (R)-4
being equally effective. The block developed quickly with (R)-1
and (R)-3 (between pulse 2 and 4) and plateaued by the sixth
pulse, whereas the frequency-dependent block of (R)-4 was
more gradual, reaching a plateau approximately after the 26th
pulse. To show that (R)-4-induced use-dependence was
reversible, we used conditions to washout any unbound (R)-4
and then tested for the extent of use-dependence. Incubation of
CAD cell with 30 μM of (R)-4 followed by a series of three
washes with fresh extracellular bath solution over a 10 min
Figure 2. Effect of N-acetylation and inclusion of a 4′-extended aryl group ((3-fluoro)benzyloxy) on (R)-1 for Na+ channel slow inactivation potency
and stereoselectivity for function. Changes in the Na+ channel maximal slow inactivation IC50 value (+20 mV) and stereoselectivity as a function of
structure.
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period led to a complete elimination of use-dependence (Figure
4B−D). Collectively, these data show that the (3-fluoro)-
benzyloxyphenyl substituent within (R)-3 and (R)-4 may be an
effective pharmacophore for inducing reversible frequency-
dependent block of Na+ currents, but its presence is not
obligatory.
Modulation of Neuronal Excitability of Dissociated
Medium Diameter DRG Neurons by Compounds 1−4.
To examine the possibility that 1−4 affect the neuronal
excitability of dissociated dorsal root ganglion (DRG) neurons,
we tested medium DRG neuronal excitability before and after
the addition of compounds. The excitability was measured by
injecting current pulses (nA) into the soma of medium
diameter DRG neurons every 30 s in order to elicit 8−12 action
potentials under control conditions prior to the addition of 100
μM of 1−4 into the recording bath. Representative recordings
(Figure 5A) and grouped data (Figure 5B) show that the
excitability (i.e., number of action potentials) of medium
diameter DRG neurons was decreased >50% by (R)-2, (R)-3,
(R)-4, and to a small extent (∼15%) by (S)-1, but not by (R)-1,
(S)-2, and (S)-4. These results suggest that the inclusion of
both the 4′-(3-fluoro)benzyloxyphenyl substituent and the N-
acetyl moiety in (R)-4 increased the potency and the
stereoselectivity for inhibition of excitability in DRG neurons.
The relative activities of 1−4 in DRG neurons paralleled the
CAD cell slow inactivation IC50 values for these compounds
(Table 1), a finding consistent with the presence on NaV1.7
channels in both of these cells.23,30,31
Structural Confirmation of the Benzyloxyphenyl Unit
B in Promoting Na+ Channel Slow Inactivation:
Determination of the Na+ Channel Properties of (R)-5,
(S)-5, (R)-6, and 7−9. The marked increase in the degree of
Na+ channel slow inactivation upon the appendage of the (3-
fluoro)benzyloxy unit to (R)-1 to give (R)-3 led us to
determine if this increased activity was associated with the
substituted benzyloxyphenyl motif B. Accordingly, we first
investigated the Na+ channel properties of (R)-5 and (S)-5, and
the corresponding 4′-aryl extended compound (R)-6. Com-
pounds 5 and 6 contained a 2-amino-3-methylpropionic acid
unit in place of the 2-amino-3-methoxypropionic acid moiety
found in 1−4.
Macroscopic sodium currents were blocked by (R)-5 almost
as effectively as (R)-1 and (R)-2,22,23 and (R)-6 was more
potent than (R)-5 (Figure 6A, B). Compared to control cells,
peak macroscopic sodium currents were inhibited by ∼72% by
(R)-5 (200 μM) and ∼74% by (R)-6 (30 μM) (Figure 6B).
Neither (R)-5 nor (S)-5 greatly affected the extent of slow
inactivation (Figure 6C, D), while the corresponding 4′-aryl
extended compound (R)-6 displayed robust slow inactivation at
a concentration even 5-fold lower than that employed for both
enantiomers of 5. The lack of Na+ channel slow inactivation for
5 was not surprising despite the excellent antiseizure properties
provided by (R)-5 (Table 1). Previous anticonvulsant
structure−activity relationship (SAR) studies indicated that
the C(2)-hydrocarbon amino acid derivatives, such as (R)-5,
likely interacted differently with receptors or at different
receptors that control neuronal hyperexcitability than (R)-2,
and possibly (R)-1.11,12,32 As with compounds (R)-1−(R)-4, an
analysis of V1/2 and k values derived from the Boltzmann fits
showed that there were no changes in the steady-state
activation properties of Na+ currents between CAD cells
treated with DMSO control or the highest concentrations of
(R)-5, (S)-5, and (R)-6 (Figure 6E). Steady-state, fast
inactivation curves of Na+ currents from DMSO- and (R)-5-,
(S)-5-, and (R)-6-treated CAD cells were well fitted with a
single Boltzmann function (R2 > 0.9914 for all three
conditions). Compared with the ∼18.1 mV shift in V1/2 of
fast inactivation in the hyperpolarizing direction observed in the
presence of (R)-4 (30 μM), the shifts caused by the other
agents were minimal: 0.8 mV, (R)-5 (500 μM; n = 8); 0.9 mV,
(S)-5 (500 μM; n = 7); and 0.9 mV, (R)-6 (100 μM; n = 3;
Figure 6E) (p < 0.05 vs DMSO control; Student’s t test). In
contrast, the excitability of DRGs was inhibited in an
enantioselective fashion by 100 μM (R)-5 but not (S)-5. As
with the slow inactivation, the corresponding 4′-aryl extended
compound (R)-6 (100 μM) also inhibited excitability compared
to DMSO control (Figure 6F; p < 0.05 vs DMSO control,
Student’s t test). We have attributed the pronounced Na+
channel properties of (R)-6 to the presence of the (3-
fluoro)benzyloxyphenyl pharmacophore in this compound.
Next, we explored the electrophysiological properties
associated with the (3-fluoro)benzyloxyphenyl unit found in
3, 4, and (R)-6. Thus, we tested (3-fluoro)benzyl phenyl ether
(7), 4-((3′-fluoro)benzyloxy)benzylamine (8),10 and N-4-((3′-
fluoro)benzyloxy)benzyl acetamide (9).10 These three com-
pounds contain a substituted benzyloxyphenyl B group but are
devoid of the adjacent amino acid unit.
Figure 3. Effect of N-acetylation and 4′-aryl extension in N-benzyl 2-
amino-3-methoxypropionamide on activation and fast inactivation
properties of Na+ currents in CAD cells. Values for V1/2, the voltage of
half-maximal activation (A) or inactivation (B), were derived from
Boltzmann distribution fits to the individual recordings and averaged
to determine the mean (±SEM) voltage dependence of activation (A)
or inactivation (B), respectively. The voltage protocol used to evoke
current responses is shown adjacent to the curves. Representative
Boltzmann fits for 0.1−1% DMSO (control) and various concen-
trations of the compounds are shown. The V1/2 and k (slope; not
shown) of activation (A) were not different among any of the
compounds tested (p > 0.05, one-way ANOVA). Compound (R)-4
(30 μM) induced a ∼18.1 mV hyperpolarizing shift in the V1/2 of fast
inactivation (B), while its enantiomer (S)-4 (500 μM) caused a 15.8
mV shift. For all experiments, data are from 3−9 cells per condition.
ACS Chemical Neuroscience Research Article
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We observed that the (3-fluoro)benzyloxyphenyl units in 7−
9 induced almost similar levels of maximal Na+ channel slow
inactivation (Figure 7A, B) with maximal slow inactivation IC50
values of 2.3 μM for 7, 10 μM for 8, and 11.9 μM for 9 (Table
1). Again, as with compounds (R)-1−(R)-4, an analysis of V1/2
and k values derived from the Boltzmann fits showed that there
were no changes in the steady-state activation properties of Na+
currents between CAD cells treated with DMSO control or the
highest concentrations of 7−9 (Figure 7C). Steady-state, fast
inactivation curves of Na+ currents from DMSO- and 7−9−
treated CAD cells were well fitted with a single Boltzmann
function (R2 > 0.9908 for all three conditions). Compared with
the ∼18.1 mV shift in V1/2 of fast inactivation in the
hyperpolarizing direction observed in the presence of (R)-4
(30 μM), the shifts caused by the other agents were 17.9 mV, 7
(100 μM; n = 4); 18 mV, 8 (100 μM; n = 6); and 12.1 mV, 9
(100 μM; n = 6, Figure 7C) (p < 0.05 vs DMSO control;
Student’s t test). We tested compounds 7 and 8 at a
concentration of 100 μM, and observed notable frequency
(use)-dependent blockage of Na+ currents by the 10th pulse
(data not shown). Finally, robust inhibition of the excitability of
DRGs was observed with 100 μM of 7−9 (p < 0.05 vs DMSO
control; Student’s t test; Figure 7D). Collectively, these results
indicated that the (3-fluoro)benzyloxyphenyl unit promoted
frequency-dependency blockage of currents and a slow
inactivation conformational change in Na+ channels.
Modulation of hNaV1.1 by (R)-2 and (R)-4. We found
that while both (R)-2 and (R)-4 displayed exceptional
anticonvulsant activity in the MES test (Table 1, MES ED50
(mg/kg, mice, ip): (R)-2, 4.5; (R)-4, 13), the CAD slow
inactivation IC50 value for (R)-4 was 400-fold lower (more
potent) than (R)-2 (Table 1, maximal slow inactivation IC50 at
+20 mV (μM): (R)-2, 120; (R)-4, 0.30). Several factors may
account for the lack of correlation of the whole animal
anticonvulsant data with the CAD cellular electrophysiological
data. One of these is that CAD cells are likely composed of
NaV1.7, NaV1.1, and NaV1.3 channels, where NaV1.7 mRNA is
expressed at 15- and 30-fold higher levels compared with
mRNA levels of NaV1.1 and NaV1.3, respectively.
23 NaV1.7 is
highly expressed in the peripheral nervous system and not in
the central nervous system (CNS).30,31 NaV1.1 mutations have
been linked to generalized epilepsy with febrile seizures, as well
as severe myoclonic epilepsy of infancy;33 therefore, we next
asked if (R)-2 and (R)-4 could affect slow inactivation of this
channel, and if the slow inactivation IC50 values for this CNS
Na+ channel isoform would parallel the observed MES ED50
values. As there is no selective blocker for NaV1.3, we could not
isolate NaV1.1 in CAD cells, and instead chose to determine the
electrophysiological properties of (R)-2 and (R)-4 on hNaV1.1
stably expressed in human embryonic kidney 293 (HEK293)
cells.
Compound (R)-4, which has both a 4′-(3-fluoro)-
benzyloxyphenyl substituent and a N-acetyl moiety, demon-
strated a higher extent of slow inactivation than (R)-2 at both
−50 mV and at +20 mV (a voltage at which maximal slow
inactivation was observed) (Figure 8C−F). The maximal slow
inactivation IC50 at +20 mV was 120-fold lower with (R)-4 (4
μM) compared with (R)-2 (480 μM); the activation and fast-
inactivation properties of NaV1.1 were not affected by the
compounds (Figure 8G). We also examined the rate time
Figure 4. Frequency-dependent block of CAD cell Na+ currents by selected compounds. (A) The frequency dependence of block was examined by
holding cells at the hyperpolarized potential of −80 mV and evoking currents at 10 Hz by 20 ms test pulses to −10 mV. (B) Representative overlaid
traces are illustrated by pulses 1, 10, 20, and 30 for control (predrug) and in the presence of 30 μM (R)-1, (R)-2, (R)-3, and (R)-4. Traces for (R)-4
following a series of three washes (2 mL each) in extracellular bath solution over a 10 min period are also shown. (C) Summary of average
frequency-dependent decrease in current amplitude (±SEM) produced by the indicated compounds but not by control conditions. (D)Summary of
the maximal decrement in current amplitude observed at the end of the 30-pulse train for predrug (control) and 30 μM (R)-1, (R)-2, (R)-3, and (R)-
4. (R)-1, (R)-3, and (R)-4 showed a significant decrease in current amplitude compared with control (*, p < 0.05, one-way ANOVA with Dunnett’s
posthoc test). Note the rapid frequency-dependent facilitation of block by (R)-1, (R)-3, and (R)-4 that was observed beginning as early as pulse 2
(arrow). Washout of cells incubated with 30 μM (R)-4 led to a complete elimination of use-dependence (#, p > 0.05, one-way ANOVA with
Dunnett’s posthoc test). Numbers in parentheses are the number of cells patched per condition.
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course of block development by these agents. Block develop-
ment was examined by holding the cells at −120 mV in the
absence or presence of 100 μM (R)-2 or (R)-4, prepulsing the
cells to 0 mV for varying amounts of time to allow block to
develop, hyperpolarizing the cells to −120 mV for 20 ms to
allow unbound channels to recover from fast inactivation, then
stepping the cells to 0 mV for 20 ms to determine the fraction
of channels available for activation (Figure 8H). The reduction
in the fraction of current available is indicative of the time
course for the development of slow inactivation. The time
course for reducing channel availability without drug, as well as
in the presence of (R)-2 and (R)-4, was biphasic, with a fast
component likely representing block development of fast-
inactivated channels and a slow component consistent with the
time course of slow inactivation development (Figure 8H). The
time constant for block development was ∼25-fold faster in
cells treated with (R)-4 (100 μM) compared with vehicle- or
(R)-2 (100 μM)-treated cells. (R)-4 significantly reduced the
fraction of current at all times between 50 and 8000 ms (Figure
8H) compared with control or (R)-2-treated cells (p < 0.05,
one-way ANOVA with Dunnett’s posthoc test). Finally, we
tested if (R)-2 and (R)-4, could elicit frequency-dependent
Figure 5. DRG neuronal excitability following application of N-benzyl
2-amino-3-methoxypropionamide derivatives. (A) Representative
recordings of medium diameter DRG neuronal firing before and
during application of compounds (R)-2, (S)-2, and (R)-3. Neuronal
excitability is significantly decreased following 100 μM (R)-2, (R)-3,
and (R)-4, but not (S)-2. (B) Group data. Box plots (with overlapping
data points representing number of action potentials from each cell)
showing mean number of action potentials ± SEM elicited by current
injection in medium diameter DRG neurons during baseline control
conditions and in the presence of 100 μM of the indicated
compounds. Asterisks indicate statistically significant differences in
fraction of current available between predrug (control) and (R)
compounds (*, p < 0.05, one-way ANOVA with Dunnett’s posthoc
test). Hash mark indicates a statistically significant difference in
fraction of current available between (R)- and (S)-enantiomers. For all
experiments, data are from 8−11 cells per condition from at least three
different rats.
Figure 6. Effects of N-benzyl 2-amino-3-methylpropionamides (R)-5
and (S)-5, and the corresponding 4′-aryl extended derivative (R)-6 on
slow inactivation, activation, and fast-inactivation of Na+ currents in
CAD cells, and firing properties of sensory neurons. (A)
Representative peak Na+ current responses, evoked by a step to 0
mV from a holding potential of −80 mV, of CAD cells treated with
0.5% DMSO (control), 200 μM (R)-5, or 30 μM (R)-6. (B) Summary
of current−voltage (I−V) relationships for CAD cells treated with the
compounds illustrated in A (n = 3−5 each). (C) Summary of steady-
state, slow inactivation curves for CAD cells treated with DMSO
(control), 500 μM (R)-5 and (S)-5, or 100 μM (R)-6. Some drug-
induced slow inactivation was apparent in CAD cells treated with (S)-
5 with more pronounced slow inactivation observed with (R)-6, while
almost no slow inactivation was observed with (R)-5. Some error bars
are smaller than the symbols. (D) Summary of the fraction of current
available at −50 mV for CAD cells in the absence or presence of (R)-
or (S)-enantiomers of the indicated compounds. Asterisks indicate
statistically significant differences in fraction of current available
between predrug and (R)- and (S)-compounds (p < 0.05, one-way
ANOVA with Dunnett’s posthoc test). Hash mark indicates a
statistically significant difference in fraction of current available
between (R)- and (S)-enantiomers. Numbers in parentheses are the
number of cells patched per condition. The half-maximal values for
slow inactivation for these compounds are shown in Table 1. (E)
Values for V1/2, the voltage of half-maximal activation or inactivation,
were derived from Boltzmann distribution fits to the individual
recordings and averaged to determine the mean (±SEM) voltage
dependence of activation or inactivation, respectively. The voltage
protocol used to evoke current responses is shown above the curves.
Representative Boltzmann fits for 0.1−1% DMSO (control) and
various concentrations of the compounds are shown. The V1/2 and k
(slope; not shown) of activation were not different among any of the
compounds tested (p > 0.05, one-way ANOVA). All compounds
induced a ∼8 mV hyperpolarizing shift in the V1/2 of fast inactivation.
For all experiments, data are from 6−9 cells per condition. F. Box plots
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block. A train of 30 test pulses (20 ms to −10 mV) was
delivered from a holding potential of −80 mV at 10 Hz (Figure
8I). The available current in control cells and cells in the
presence of the compounds was calculated by dividing the peak
current at any given pulse (pulseN) by the peak current in
response to the initial pulse (pulse1). Both (R)-2 and (R)-4 did
not reduce current amplitude compared with control (Figure
8I, J). Our results point to the potent activity of (R)-4 on slow
inactivation of NaV1.1 channels.
■ CONCLUSION
In this study, we asked if the cellular pharmacology for
compounds 1−4 was similar. We focused on the Na+ channel
because the AED (R)-2 and the 4′-aryl-extended compound
(R)-4 have been shown to facilitate entry of Na+ channels into
the slow inactivation state.15−17,22,23 Compounds 1−4 affected
Na+ channel slow inactivation, but the extent of slow
inactivation and the stereoselectivity for slow inactivation was
markedly affected by terminal amine acetylation and extension
of the 4′-aryl group (Figure 2). Compound (R)-4 was the most
potent Na+ channel modulator; it was 390-fold more effective
in inducing maximal Na+ channel slow inactivation (at +20
mV) than (R)-2. Moreover, (R)-4 was 1100-fold more active
than its stereoisomer (S)-4. By comparison, (R)-2 was only
>21-fold more active than (S)-2 in inducing Na+ channel slow
inactivation. Our findings indicated that the pronounced
activity and stereoselectivity of (R)-4 was uniquely influenced
by a combination of the N-acetyl and the (3-fluoro)-
benzyloxyphenyl structural units, and where the concurrent
incorporation of both groups contributed to its Na+ channel
slow inactivation activity. We also found that the 4′-aryl
extended compounds (R)-3 and (R)-4 exhibited frequency
(use)-dependent inhibition of Na+ currents. Frequency-
dependent block is a powerful way to control neuronal
hyperexcitability in rapidly firing neurons.
Since the extended 4′-aryl substituent in (R)-4 significantly
increased Na+ channel slow inactivation, we determined the
Na+ channel properties of (R)-6 and 7−9, and documented
that the (3-fluoro)benzyloxyphenyl moiety in these compounds
contributed to their observed Na+ channel slow inactivation
properties (maximal slow inactivation IC50 at +20 mV (μM):
(R)-6, 0.60; 7, 2.3; 8, 10; 9, 12) (Table 1). Moreover, we
showed that 7 and 8 inhibited Na+ currents in a frequency
(use)-dependent manner. Collectively, our findings indicated
that the substituted benzyloxyphenyl unit B is an effective
pharmacophore for modulating Na+ channel function and
provides a structural unit for the design of neurological agents
targeting these channels. Importantly, our earlier SAR studies10
demonstrated that considerable structural latitude exists for the
4′-aryl-extended unit in compounds such as 3, 4, and 6, and
that these compounds exhibited excellent Na+ channel slow
and, in some cases, fast inactivation properties.22 Currently, we
are exploring the utility of this general pharmacophore unit for
the design of novel neurological agents.
We tested the effects of (R)-2 and (R)-4 on hNaV1.1 stably
expressed in HEK293 cells. We found that (R)-4 was 120-fold
more effective than (R)-2 in transitioning Na+ channels to the
slow inactivation state (maximal slow inactivation IC50 at +20
mV (μM): (R)-2, 480; (R)-4, 4). A similar pattern was
observed in CAD cells, where approximately 50% of the Na+
Figure 6. continued
(with overlapping data points representing number of action potentials
from each cell) showing mean number of action potentials ± SEM
elicited by current injection in medium diameter DRG neurons during
baseline control conditions and in the presence of 100 μM of the
indicated compounds. Asterisks indicate statistically significant differ-
ences in fraction of current available between predrug (control) and
(R) compounds (*, p < 0.05, one-way ANOVA with Dunnett’s
posthoc test). Hash mark indicates a statistically significant difference
in fraction of current available between (R)- and (S)-enantiomers. For
these experiments, data are from 8−11 cells per condition from at least
two different rats.
Figure 7. Effects of the substituted benzyloxyphenyl motif B without
the adjacent amino acid unit in compounds 7−9 on slow inactivation,
activation, and fast-inactivation of Na+ currents in CAD cells, and
firing properties of sensory neurons. (A) Summary of steady-state,
slow inactivation curves for CAD cells treated with DMSO (control)
or 100 μM of 7−9. Robust drug-induced slow inactivation was
apparent in CAD cells treated with compounds 7−9. Some error bars
are smaller than the symbols. (B) Summary of the fraction of current
available at −50 mV for CAD cells in the absence or presence of
compounds 7−9. Asterisks indicate statistically significant differences
in fraction of current available between predrug and compounds 7−9
(p < 0.05, one-way ANOVA with Dunnett’s posthoc test). Numbers in
parentheses are the number of cells patched per condition. The half-
maximal values for slow inactivation for these compounds are shown
in Table 1. (C) Values for V1/2, the voltage of half-maximal activation
or inactivation, were derived from Boltzmann distribution fits to the
individual recordings and averaged to determine the mean (±SEM)
voltage dependence of activation or inactivation, respectively. The
voltage protocol used to evoke current responses is shown above the
curves. Representative Boltzmann fits for 0.1−1% DMSO (control)
and various concentrations of the compounds are shown. The V1/2 and
k (slope; not shown) of activation were not different among any of the
compounds tested (p > 0.05, one-way ANOVA). The compounds
induced a ∼12−18 mV hyperpolarizing shift in the V1/2 of fast
inactivation. For all experiments, data are from 5−9 cells per condition.
(D) Box plots (with overlapping data points representing number of
action potentials from each cell) showing the mean number of action
potentials ± SEM elicited by current injection in medium diameter
DRG neurons during baseline control conditions and in the presence
of 100 μM of the indicated compounds. Asterisks indicate statistically
significant differences in fraction of current available between predrug
(control) and compounds 7−9 (*, p < 0.05, one-way ANOVA with
Dunnett’s posthoc test). For these experiments, data are from 8−11
cells per condition from at least 2 different rats.
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current can be attributed to NaV1.7 channels (maximal slow
inactivation IC50 at +20 mV (μM): (R)-2, 120; (R)-4, 0.30).
22
The enhanced Na+ channel activity for (R)-4 versus (R)-2
differs from their MES anticonvulsant activities, where (R)-2 is
∼3-fold more potent than (R)-4 in mice (i.p.). Thus, other
factors (e.g., pharmacokinetics) may be partially responsible for
the observed anticonvulsant activities. These results underscore
the importance of conducting both cellular electrophysiology
and in vivo testing in drug screening protocols designed to
identify new neurological agents.
Figure 8. Analysis of N-benzyl 2-acetamido-3-methoxypropionamide ((R)-2) and the 4′-(3-fluoro)benzyloxy derivative ((R)-4) on
electrophysiological properties of NaV1.1 currents in HEK293 cells. (A) Representative current traces from CAD cells in the absence (control)
or presence of the NaV1.1-selective blocker protox II (10 nM) in response to a voltage step from −80 to 0 mV for 200 ms. In the example shown, the
peak current decreased by ∼50% from a control value of 1472.6 pA to a value of 739.85 pA 15 min postapplication of protox II (10 nM). (B)
Summary of the mean ± SEM change in current relative to the current at 4 min following acquisition of whole cell (baseline) for 10 nM protox II (n
= 5) and control. There was a small buildup in current density in control cells (n = 4). The rest of the figure describes data from HEK293 cells stably
transfected with NaV1.1 (C−J). Steady-state, slow inactivation curves for HEK293 cells expressing wildtype hNaV1.1 in response to a range of
concentrations of (R)-2 (C) or (R)-4 (D). Voltage protocol for assessing slow inactivation is as described in the legend to Figure 1. (E)
Representative current traces at −50 mV from cells that underwent no treatment, or treatment with 100 μM (R)-2, and 100 μM (R)-4. As a
comparator of the extent of slow inactivation, a control trace at −120 mV (prepulse) is also shown. (F) Summary of steady-state, slow inactivation
curves for NaV1.1 HEK293 cells treated with DMSO (control), or various concentrations of (R)-2 or (R)-4. (G) Fast inactivation curves for NaV1.1
HEK293 cells in response to no treatment (control), 100 μM (R)-2, and 100 μM (R)-4. The curves are derived from Boltzmann distribution fits to
the individual recordings and averaged to determine the mean (±SEM) of steady-state inactivation (I/Imax). Voltage protocol for fast inactivation
stepped from −120 to −10 mV in 10 mV increments for a pulse duration of 500 ms. Fraction of channels available was then measured at 0 mV.
Activation curves for the no treatment (control), 100 μM (R)-2, and 100 μM (R)-4 were normalized to G/Gmax and curves were derived from
Boltzmann distribution fits as previously described. The voltage protocol for steady-state activation stepped from −80 mV to 0 mV. (H) NaV1.1
HEK293 cells were held at −120 mV, depolarized to 0 mV for 10 ms or 5 s, and then hyperpolarized to −120 mV for varying increasing durations
before testing the available current with a step depolarization to 0 mV. Data sweeps were acquired at 0.5 Hz for short recovery durations and at
slower rates for the longer recovery durations. (R)-4 caused a pronounced decrease in the rate of inactivation/inhibition recovery (by the 10 ms
prepulse) for Na+ channels, whereas (R)-2 had no effect. (I) The frequency dependence of block was examined by holding cells at the hyperpolarized
potential of −80 mV and evoking currents at 10 Hz by 20 ms test pulses to −10 mV. Representative overlaid traces are illustrated by pulses 1, 10, 20,
and 30 for control (predrug) and in the presence of (R)-2 and (R)-4. (J) Summary of average frequency-dependent decrease in current amplitude
(±SEM) produced by no treatment (control), (R)-2 or (R)-4. Neither compound induced use (*, p > 0.05, one-way ANOVA with Dunnett’s
posthoc test).
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Finally, we learned that the C(2)-hydrocarbon compound
(R)-5, despite its structural similarity to (R)-1 and (R)-2, did
not modulate Na+ channel slow inactivation activity. The
antiepileptic activity of (R)-2 has been attributed to its ability to
promote Na+ channel slow inactivation.15−17,23 Nonetheless,
(R)-5 exhibited pronounced anticonvulsant activity in the MES
test (ED50 = 15 mg/kg, mice (ip)). These findings provide an
instructive example of how molecules that share common
structural features can either interact differently with receptors
or with a different set of receptors that control neuronal
hyperexcitability and still show pronounced efficacy in the same
animal model.
■ METHODS
Materials. Synthetic procedures and analytical characterization for
compounds 1, 2, (R)-3, 4, 5, (R)-6, 8, and 9 have been previously
reported.6,10−12 Compound 7 was purchased from Sigma.
Catecholamine A Differentiated (CAD) Cells. CAD cells were
grown at 37 °C and in 5% CO2 (Sarstedt, Newton, NC) in Ham’s
F12/EMEM medium (GIBCO, Grand Island, NY), supplemented
with 8% fetal bovine serum (FBS; Sigma, St. Louis, MO) and 1%
penicillin/streptomycin (100% stocks, 10 000 U/mL penicillin G
sodium and 10 000 μg/mL streptomycin sulfate).22,23,34 Cells were
passaged every 6−7 days at a 1:25 dilution.
Human Embryonic Kidney 293 (HEK293) Cells Expressing
NaV1.1. A codon-optimized synthetic gene encoding the human
NaV1.1 (wild-type) channel open reading frame (NC_000002.11) was
transfected into HEK293 cells using the calcium phosphate
precipitation technique. After 48 h, the cells were passaged into 100
mm dishes and treated with G418 (Geneticin, Life Technologies) at
800 μg/μL to select for neomycin resistant cells. After 2 weeks,
colonies were picked and split. The colonies were then tested for
channel expression with whole-cell patch-clamp technique. The cell
line was then maintained with 500 μg/μL G418. NaV1.1 stable cell line
was grown under standard tissue culture conditions (5% CO2 at 37
°C) in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum.
Whole-Cell Patch Clamp. Whole-cell patch clamp recordings
were performed at room temperature on CAD cells using an EPC 10
Amplifier (HEKA Electronics, Germany) as described previously.22,23
Electrodes were pulled from thin-walled borosilicate glass capillaries
(Warner Instruments, Hamden, CT) with a P-97 electrode puller
(Sutter Instrument, Novato, CA) such that final electrode resistances
were 1−2 MΩ when filled with internal solutions. The internal
solution for recording Na+ currents contained (in mM): 110 CsCl, 5
MgSO4, 10 EGTA, 4 ATP Na2-ATP, 25 Hepes (pH 7.2, 290−310
mOsm/L). The external solution contained (in mM) 100 NaCl, 10
tetraethylammonium chloride (TEA-Cl), 1 CaCl2, 1 CdCl2, 1 MgCl2,
10 D-glucose, 4 4-AP, 0.1 NiCl2, and 10 Hepes (pH 7.3, 310−315
mOsm/L). Whole-cell capacitance and series resistance were
compensated with the amplifier. Series resistance error was always
compensated to be less than ±3 mV. Cells were considered only when
the seal resistance was less than 3 MΩ. Linear leak currents were
digitally subtracted by P/4.
Na+ channel fast- and slow-inactivated states were induced as
previously described.22,23 For fast inactivation, cells were held at −80
mV, stepped to inactivating prepulse potentials ranging from −120 to
−10 mV (in 10 mV increments) for 500 ms, and then the cells were
stepped to 0 mV for 20 ms to measure the available current. A 500 ms
conditioning pulse was used because it allowed all endogenous
channels to transition to a fast-inactivation state at all potentials
assayed. For slow inactivation, CAD cells were held at −80 mV and
conditioned to potentials ranging from −120 to +20 mV (in 10 mV
increments) for 5 s. Then, fast-inactivated channels were allowed to
recover for 150 ms at a hyperpolarized pulse to −120 mV, and the
fraction of channels available was tested by a single depolarizing pulse
to 0 mV for 15 ms. This brief hyperpolarization allowed the channels
to recover from fast inactivation while limiting recovery from slow
inactivation. Using this protocol, a series of compound response curves
were generated showing the normalized peak (INa) versus prepulse
potential (mV) at a given compound concentration.
Data Acquisition and Analysis. Signals were filtered at 10 kHz
and digitized at 10−20 kHz. Analysis was performed using Fitmaster
and origin8.1 (OriginLab Corporation, Northampton, MA). For
activation curves, conductance (G) through Na+ channels was
calculated using the equation G = I/(Vm−Vrev), where Vrev is the
reversal potential, Vm is the membrane potential at which the current
was recorded, and I is the peak current. Activation and inactivation
curves were fitted to a single-phase Boltzmann function G/Gmax = 1/{1
+ exp[(V − V50)/k]}, where G is the peak conductance, Gmax is the
fitted maximal G, V50 is the half activation voltage, and k is the slope
factor. Additional details of specific pulse protocols are described in
the results text or figure legends.
Animals. Pathogen-free, adult female Sprague−Dawley rats (150−
200 g; Harlan Laboratories, Madison, WI) were housed in temperature
(23 ± 3 °C) and light (12 h light: 12 h dark cycle; lights on at 07:00 h)
controlled rooms with standard rodent chow and water available ad
libitum. Experiments were performed during the light cycle. These
experiments were approved by the Institutional Animal Care and Use
Committee of Indiana University/Purdue University in Indianapolis.
All procedures were conducted in accordance with the Guide for Care
and Use of Laboratory Animals published by the National Institutes of
Health and the ethical guidelines of the International Association for
the Study of Pain. All animals were randomly assigned to either
treatment or control groups.
Preparation of Acutely Dissociated Dorsal Root Ganglion
Neurons. The L1-L6 DRGs were acutely dissociated using methods
described by Ma and LaMotte.35 Briefly, L1-L6 DRGs were removed
from naiv̈e Sprague−Dawley rats. The DRGs were treated with
collagenase A and collagenase D in HBSS for 20 min (1 mg/mL;
Roche Applied Science, Indianapolis, IN), followed by treatment with
papain (30 units/mL, Worthington Biochemical, Lakewood, NJ) in
HBSS containing 0.5 mM EDTA and cysteine at 35 °C. The cells were
then dissociated via mechanical trituration in culture media containing
1 mg/mL bovine serum albumin and trypsin inhibitor (1 mg/mL,
Sigma, St. Louis MO). The culture media was DMEM, Ham’s F12
mixture, supplemented with 10% fetal bovine serum, penicillin and
streptomycin (100 μg/mL and 100 U/mL), N2 (Life Technologies),
and 20 nM NGF (Sigma-Aldrich, St. Louis, MO). The cells were then
plated on coverslips coated with poly-L-lysine and laminin (1 mg/mL)
and incubated for 2−3 h before more culture media was added to the
wells. The cells were then allowed to sit undisturbed for 4−18 h to
adhere at 37 °C (with 5% CO2).
Current Clamp Electrophysiology. Sharp-electrode intracellular
recordings were obtained 4−18 h after dissociation using a modified
method described by Ma and LaMotte.35 Coverslips were transferred
to a recording chamber that was mounted on the stage of an inverted
microscope (Nikon Eclipse Ti, Nikon Instruments Inc., Melville, NY).
The chamber was perfused with a bath solution containing (mM): 120
NaCl, 3 KCl, 1 CaCl2, 1 MgCl2, 10 Hepes, 10 glucose, adjusted to pH
7.4 and osmolarity 300 mOsM. The recordings were obtained at room
temperature. Intracellular recording electrodes were fabricated from
borosilicate glass (World Precision Instruments, Sarasota, FL) and
pulled on a Flaming/Brown micropipet puller (P-98, Sutter Instru-
ments, Novato, CA). Electrodes were filled with 1.0 M KCl
(impedance: 40−80 MΩ) and positioned by a micromanipulator
(Newport Corporation, Irvine, CA). A −0.1 nA current injection was
used to bridge-balance the electrode resistance. Prior to electrode
impalement, the size of the soma to be recorded was classified
according to its diameter as small (≤30 μm), medium (31−45 μm),
and large (≥45 μm). Only medium size neurons were used in these
experiments as these neurons consistently exhibited the ability to fire
multiple action potentials without accommodation. Electrophysio-
logical recordings were performed with continuous current-clamp in
bridge mode using an AxoClamp-2B amplifier, stored digitally via
Digidata 1322A interface, and analyzed offline with pClamp 9 software
(Axon Instruments, Union City, CA). A neuron was accepted for study
only when it exhibited a resting membrane potential more negative
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than −45 mV. Action potentials were evoked by injecting current steps
of 1 s duration through the intracellular recording electrode from 0.1
nA in increments of 0.1 nA until evoking 8−10 action potentials per
current pulse, or reaching 4 nA. Baseline neuronal excitability was
measured by injecting 1 s current pulses into the soma every 30 s.
Following three control current injections, compounds were applied to
the coverslip (final concentration of 100 μM) and current injections
continued every 30 s. Neuronal excitability was measured as number of
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